Stealth announces new appointments to senior leadership team
Dr. Weaver has more than 30 years of experience in both academic and industry settings, including an extensive background in the design and operation of multi-center clinical trials of new therapeutics for cardiovascular disease.
He has served as a past president of the American College of Cardiology, as a healthcare consultant for Navigant Consulting, Inc. and as Vice President and System Medical Director of Cardiovascular Services for Henry Ford Health System.
He received his M.D. from Tufts University School of Medicine.
Mr. Geffken brings more than 20 years of experience in the life science industry to Stealth. Previously, Mr. Geffken served as Chief Operating Officer of Seaside Therapeutics, Inc. and as the Chief Operating Officer or Chief Financial Officer of several publicly traded and privately held life science companies.
He is Founding Managing Director of Danforth Advisors, LLC.
Mr. Geffken received his M.B.A. from the Harvard Business School.
In addition, Stealth announced that Jim Carr, Pharm.D. has been promoted to Chief Clinical Development Officer.
Dr. Carr has been with Stealth since 2014 as Vice President of Clinical Development. He has 20 years of industry experience in the areas of clinical development, medical affairs, lifecycle management, new product planning and global marketing.
Previously, he served as Executive Director in the Global Cardiovascular Franchise at GlaxoSmithKline and a clinical faculty member at the University at Buffalo-SUNY School of Pharmacy.
He received a Pharm.D. from the University of Minnesota. ■
LATEST MOVES FROM Massachusetts
- Chiasma re-appoints Roni Mamluk to board
- BayCoast Bank appoints James Wallace as CFO
- Pulmatrix appoints Amit D. Munshi to board
- Syros Pharmaceuticals appoints Srinivas Akkaraju to board
- Merrimack Pharma names Sergio Santillana as CMO
More inside POST
Biomar acquires Alimentsa Companies